华熙生物2025年净利润同比增长67.03% 加速从“规模扩张”向“质量增长”转型

Core Insights - Huaxi Biological Technology Co., Ltd. reported a total revenue of 4.217 billion yuan for the fiscal year 2025, representing a year-on-year decline of 21.49%. However, the net profit attributable to the parent company reached 291 million yuan, marking a significant increase of 67.03% [2][3] Revenue Performance - The decline in revenue is attributed to the company's proactive structural adjustments, which involved optimizing the C-end brand system, product structure, and channel models, leading to a temporary revenue contraction [2] - The company has focused on reducing inefficient brands and sales activities based solely on revenue metrics, which has impacted short-term income [2] Profitability Improvement - The strategic adjustments have resulted in a notable improvement in profitability, with management and sales expenses decreasing by over 10% and 30% year-on-year, respectively [2] - Cost reduction measures included integrating overlapping departments, optimizing organizational levels, and improving inventory structure, allowing the company to shift from "scale expansion" to "quality growth" [2] Research and Development - Huaxi Biological continues to deepen its focus on glycoscience and cell biology, leveraging a synthetic biology platform to accelerate the conversion of research outcomes into products, laying a foundation for long-term development [2] - The application of digital and AI technologies in production, manufacturing, and supply chain management has further enhanced operational efficiency [2] Additional Factors - The increase in government subsidies, fair value changes of investment projects, and gains from equity investment disposals contributed to the significant change in net profit, especially given the low base of 174 million yuan in the same period of 2024 [3]